New inhaled therapy tested to fight stubborn lung infections in CF
Disease control
Recruiting now
This study is testing the safety of a new inhaled medication called RSP-1502 for people with cystic fibrosis who have a chronic lung infection called Pseudomonas aeruginosa. Participants will breathe in the medication through a nebulizer for 14 days. The goal is to see if this tr…
Phase: PHASE1, PHASE2 • Sponsor: Respirion Pharmaceuticals Pty Ltd • Aim: Disease control
Last updated Mar 12, 2026 13:52 UTC